Skip to NavigationSkip to content

Johnson & Johnson

$417 million case against J&J thrown out

A judge in California has thrown out the lawsuit made by a woman who had alleged that Johnson & Johnson’s talc-based baby powder product had caused her ovarian cancer.

The original ruling in the case had taken the side of the prosecution, with a $417 million verdict against the company – awarding Eva Echeverria $70 million in compensation and $347 in punitive damages.

J&J’s third quarter: The good and the bad

It was a mixed bag for Johnson & Johnson on its announcement of third quarter results. It could largely be broken down into two areas: in the short-term, good, and in the long-term, not so much.

To begin with the good news, it posted that its revenues had risen by 10%, up to $19.7 billion. This beat analysts’ expectation by around 5%, with the pharmaceutical business performing better than expected with 15% growth.

J&J exits insulin pump business, rival looks to scoop patients

Johnson & Johnson’s Animas Corporation will cease business and close operations after the pharma giant could not find a buyer to take it off its hands. The decision from the second largest provider of insulin pumps will see 90,000 customers needing to find a new insulin pump provider.

FDA rejects J&J’s treatment for rheumatoid arthritis

Perhaps unsurprisingly, after the FDA’s advisory committee had voted 12-1 against approval of Johnson & Johnson’s drug, the FDA returned to the company with a rejection of its rheumatoid arthritis treatment.

Sirukumab had once been considered a sure-fire blockbuster for the company, but such hopes floundered after the advisory committee returned their resounding rejection and partner to the drug, GSK, abandoned ship.

J&J backs out of $1.1 billion hep C deal, wiping 22.2% from Achillion's stock

Johnson & Johnson has announced that it is to back out of a $1.1 billion deal with Achillion Pharmaceuticals to develop the firm’s hepatitis C drug pipeline. The news sent Achillion’s stock reeling, wiping away 22.2% of its value.

The deal was originally made back in 2015, where J&J agreed to pay Achillion clinical, regulatory and sales milestones, in addition to royalties. In addition to this, J&J also acquired $225 million of Achillion’s stock as part of the partnership.

J&J offers $134,000 grant to find the best start-up in South Korea

Johnson & Johnson is doubling down its efforts to grow its business in East Asia by identifying and recruiting promising healthcare and biopharma start-up companies across South Korea as part of its venture acceleration programme. 

J&J uses FDA Priority Review Voucher to snag psoriasis approval

The FDA has handed out another approval, as the agency now easily surpasses last year’s figure of 22 already, this time as Janssen was granted approval for its treatment of moderate-to-severe psoriasis.

The company used its Priority Review Voucher to shave off four months from the approval process for the drug, which is thought to hold the potential to become a new blockbuster treatment in the area.

Tremfya (guselkumab) enters the market to join Novartis’ market-leader, Cosentyx, Eli Lilly’s Taltz and Valeant’s Siliq.

Johnson & Johnson face major lawsuit over vaginal mesh

Johnson & Johnson will face a lawsuit after 700 Australian women launched a class action suit over the failures of its vaginal mesh implant. The case is potentially serious for the pharma giant, as over 100,000 women are thought to have undergone the procedure worldwide – indicating that there will be many further cases for the company to face.

Making strides in hepatitis

Published on 19/06/17 at 09:59am

Pharmafocus caughtup with Lawrence Blatt, Janssen’s Global Therapeutic Area Head, Infectious Diseases and Vaccines, to discuss the progress being made in the battle against hepatitis through pushing down treatment durations and investigative new mechanisms.

Where does hepatitis treatment currently stand today?

Latest prostate cancer research could provide boost for J&J

Research funded by Cancer Research UK has found that abiraterone added to hormone therapy improved survival by over a third in those suffering from prostate cancer. The trial involved Johnson & Johnson’s Zytiga and could become a new standard of treatment, with it taking advantage of the results to make new applications on the indication worldwide.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches